Ocular Therapeutix™ adopts BSI’s CTMS software for its Ophthalmology clinical trials
BSI Life Sciences today announced biopharma Ocular Therapeutix (NASDAQ: OCUL) as its latest client to go live with its c…
BSI Life Sciences today announced biopharma Ocular Therapeutix (NASDAQ: OCUL) as its latest client to go live with its c…
Broad portfolio for biologics, including cell and gene therapy products Digitally connected Drug Delivery Devices for s…
Breites Portfolio für Biologika, einschließlich Zell- und Gentherapieprodukte Digital vernetzte Drug Delivery Devices…
With innovative, solution-oriented, and sustainable developments, the Gerresheimer team presents itself at Pharmapack an…
With DropControl, Gerresheimer has developed a new dropper insert for modern drugs with low viscosity for ophthalmology,…
Edmund Optics®, a leading global manufacturer and supplier of optical components, announces the recipients of its 2022 E…
On August 27, Gerresheimer Boleslawiec S.A. celebrates its 70th anniversary in Poland. Founded in 1952, the industrial p…
Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor…
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exc…
An Italy-based specialist serving the optical industry is benefitting from the precision and high-quality motion of NSK…